$8.03
6.63%
Nasdaq, Mon, Mar 31 2025
ISIN
US0198181036
Symbol
ALVR
Sector
Industry

AlloVir Inc Stock price

$8.03
-1.77 18.06% 1M
-10.57 56.82% 6M
-1.63 16.87% YTD
-10.48 56.62% 1Y
-147.22 94.83% 3Y
-575.94 98.62% 5Y
-575.94 98.62% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.57 6.63%
ISIN
US0198181036
Symbol
ALVR
Sector
Industry

Key metrics

Market capitalization $150.18m
Enterprise Value $31.89m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.36
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-55.26m
Free Cash Flow (TTM) Free Cash Flow $-67.71m
Cash position $118.29m
EPS (TTM) EPS $-11.75
P/E forward negative
Short interest 7.85%
Show more

Is AlloVir Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

AlloVir Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast AlloVir Inc:

1x Sell
100%

Analyst Opinions

1 Analyst has issued a forecast AlloVir Inc:

Sell
100%

Financial data from AlloVir Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 43 43
11% 11%
-
- Research and Development Expense 12 12
90% 90%
-
-55 -55
69% 69%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -55 -55
70% 70%
-
Net Profit -59 -59
69% 69%
-

In millions USD.

Don't miss a Thing! We will send you all news about AlloVir Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AlloVir Inc Stock News

Neutral
GlobeNewsWire
14 days ago
Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina
Neutral
GlobeNewsWire
20 days ago
Combined company expected to trade on Nasdaq under “KLRS” after closing Combined company expected to trade on Nasdaq under “KLRS” after closing
Neutral
Business Wire
about 2 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AlloVir, Inc. (the “Company”) (NasdaqCM: ALVR) and Kalaris Therapeutics. Pursuant to the terms of the agreement, upon completion of the Merger, pre-Merger AlloVir stockholders are expected to own approximately 2...
More AlloVir Inc News

Company Profile

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in 2013 and is headquartered in Houston, TX.

Head office United States
CEO Andrew Oxtoby
Employees 6
Founded 2013
Website www.kalaristx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today